Myelodysplastic syndrome (MDS) describes a group of bone marrow malignancies with
variable morphologies and heterogeneous clinical features. The aim of this study was to …

Myelodysplastic syndromes (MDS) are a group of clonal hematological disease with high
risk of progression to AML. Accurate risk stratification is of importance for the proper …

Abstract Background Myelodysplastic Neoplasms (MDS) are clonal stem cell disorders
characterized by ineffective hematopoiesis and progression to acute myeloid leukemia …

Background: Matrix metalloproteinase-2 (gelatinase-A, Mr 72,000 type IV collagenase, MMP-
2) and-9 (gelatinase-B, Mr 92,000 type IV collagenase, MMP-9) are key molecules that play …

Objective: To determine the frequency of cytogenetic abnormalities in patients diagnosed as
primary myelodysplastic syndrome (MDS) using conventional karyotyping. Study Design …

Background The karyotype is a major determinant of prognosis in myelodysplastic syndrome
(MDS). Details of the cytogenetic profile of MDS in South Asia are limited because …

Background Myelodysplastic syndrome (MDS), a disorder of clonal hematopoiesis, is an
important clinical entity, but most of the studies available are conducted among the Western …

Karyotype is the most important diagnostic and prognostic parameter in myelodysplastic
syndromes (MDS) and is abnormal in approximately 50% of patients. We emphasized the …

Bone marrow (BM) mesenchymal stem/stromal cells (MSCs) are vital in hematopoiesis.
Whether BM‐MSCs alter their characteristics in Myelodysplastic Syndromes (MDS) is still …

Objective: Myelodysplastic syndrome (MDS) is a group of bone marrow diseases that not
only have variable morphological presentation and heterogeneous clinical courses but also …